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Studies utilizing genetic and pharmacological manipulations in rodent models and neuronal cultures have revealed myriad roles
of brain-derived neurotrophic factor (BDNF). Currently, this knowledge of BDNF function is being translated into improvement
strategies for several debilitating neurological disorders in which BDNF abnormalities play a prominent role. Common among
the BDNF-related disorders are irregular traﬃcking and release of mature BDNF (mBDNF) and/or its prodomain predecessor,
proBDNF. Thus, investigating the conditions required for proper traﬃcking and release of BDNF is an essential step toward
understanding and potentially improving these neurological disorders. This paper will provide examples of disorders related to
BDNF release and serve as a review of the techniques being used to study the traﬃcking and release of BDNF.
1.Introduction
Molecular, electrical, and structural properties of neurons
are all regulated in part by the most widely expressed neu-
rotrophin in the mammalian central nervous system (CNS),
brain-derived neurotrophic factor (BDNF). Mature BDNF
(mBDNF) binds with high aﬃnity to the tyrosine kinase
receptor,TrkB,andmostoftheeﬀectsofBDNFareduetothe
intracellular cascades resulting from BDNF-TrkB signaling.
The prodomain predecessor of BDNF, proBDNF, is also
secreted, but preferentially binds to the pan-neurotrophin
receptor p75NTR, triggering intracellular cascades with very
diﬀerent eﬀects than those elicited by BDNF-TrkB signaling
[1, 2].
BDNF and proBDNF play essential roles in neuronal
development, plasticity, diﬀerentiation, and survival (see [3,
4] for reviews). With such widespread function, there is a
substantial possibility for BDNF malfunction. In Alzheimer’s
disease patients, BDNF mRNA was reduced 50% in nuclei
of the basal forebrain, the origin of the cholinergic neu-
rons that innervate the cortex and hippocampus, and a
region associated with the cognitive deterioration seen in
Alzheimer’s [5]. Neuronal survival is compromised in Hunt-
ington’s disease as a result of an attenuated TrkB-Shc sig-
naling pathway [6]. Thus, many neurological disorders have
been associated with BDNF, with abnormalities occurring
anywhere from the transcription of the BDNF gene to the
receptor-mediated signaling cascades.
Between the transcription and signaling of BDNF are
the equally important traﬃcking and release of it. BDNF in
its pro- and/or mature form is packaged in the trans-Golgi
network(TGN)andwillseeoneoftwopossiblefates:storage
in dense-core granules for release via activity-regulated
secretory pathways, or smaller BDNF vesicles can bud oﬀ
from the TGN for release through a constitutive pathway
(reviewed in [7]). Mice with a genetic knockout (KO) of
carboxypeptidase E, a transmembrane receptor in the TGN
that directs proBDNF to the secretory pathway, exhibited
a wide range of problems in dendritic spine morphology,
accompaniedbybehavioralcomplicationsrelatedtolearning
and memory [8] .Ar e c e n ts t u d yf o u n dv e r yd i ﬀerent
patterns of intracellular cascades, yielding large observable2 Neural Plasticity
Table 1: Summary of advantages and disadvantages of using BDNF ELISA, BDNF-eGFP, BDNF-pHluorin.
Method Primary purpose Advantages Disadvantages References
BDNF ELISA
Quantify levels of BDNF in
homogenized tissue, or
levels of released BDNF if
using ELISA in situ
Genetic manipulations are
unnecessary. Endogenous
BDNF levels can be
quantitatively measured with
pg sensitivity.
proBDNF-speciﬁc ELISA kits
are available. If using ELISA in
situ, the amount of released
BDNF can be accurately
quantiﬁed, and tissue need
not be destroyed.
Cannot identify sites of
BDNF release, and cannot
observe traﬃcking of
BDNF vesicles. ELISA is
performed over the course
of hours, and changes in
BDNF cannot be observed
in real time. ELISA in situ
inhibits BDNF-TrkB
signaling.
[13, 19, 20, 22,
24, 51, 57, 59, 65]
BDNF-eGFP Visualize BDNF traﬃcking
and release in real time
BDNF vesicle dynamics can be
observed throughout the cell.
Sustained vesicle release can
be observed by a relative
decline in ﬂuorescence. Can
be used in conjunction with
western blot to determine
relative levels of mBDNF and
proBDNF. Downstream
signaling of BDNF-eGFP
release is similar to that of
BDNF.
cDNA plasmids for
BDNF-eGFP must be
introduced by transfection
or viral transduction,
which can be harsh on cells,
and/or can lead to artiﬁcial
overexpression of BDNF.
Cannot quantify absolute
levels of released BDNF.
[11, 12, 28–
31, 33, 35, 36]
BDNF-pHluorin Visualize BDNF vesicle
release kinetics in real time
The pH sensitivity of
pHluorin enables
discrimination between
sustained and transient
vesicular fusion, which is
indicative of how much BDNF
is diﬀusing out of each vesicle.
Downstream signaling of
BDNF-pHluorin release is
s i m i l a rt ot h a to fB D N F .
Because ﬂuorescence is
quenched at low pH,
BDNF-pHluorin is diﬃcult
to track while inside of
acidiﬁed vesicles, making
this tool unsuitable for
BDNF traﬃcking studies.
The same disadvantages as
BDNF-eGFP also apply.
[10, 85]
diﬀerences in spine morphology, resulting from acute or
gradual exogenous BDNF application, even when ﬁnal
BDNF concentration was held constant [9]. These results
demonstrate that not only are concentrations of BDNF
important for neuronal function, but so are the ways in
which BDNF is released—either constitutively (analogous to
gradual and chronic application) or in an activity-dependent
manner (analogous to rapid and acute application).
Within recent years, knowledge of BDNF traﬃcking and
release,andthetechniques usedtostudy them,hasimproved
dramatically [10–13]. With these advancements, research
is now able to shift from investigation of normal BDNF
dynamics to the study of abnormal BDNF dynamics as they
pertain to particular disorders. However, only some such
investigations have been conducted [14–16]. In this paper,
three tools currently being used to study BDNF traﬃcking
and/or release are reviewed: BDNF ELISA, BDNF tagged
with enhanced green ﬂuorescent protein from the jelly-
ﬁsh Aequorea victoria (BDNF-eGFP), and BDNF-pHluorin,
which is tagged with the superecliptic variant of pHluorin, a
pH-sensitive mutant of eGFP (see Table 1). Discussion will
then shift towards the value of these methods in studying
the role of BDNF in the following neurological disorders:
(i) Val66met, a subclinical condition deﬁned by a common
single nucleotide polymorphism in (SNP) in the pro region
of BDNF. It is associated with memory complications
and decreased hippocampal and cortical volume [17]; (ii)
neurodevelopmental disorders such as Rett syndrome and
Fragile X syndrome; (iii) Huntington’s disease, an inherited
neurodegenerative disorder.
2.BDNF ELISA
Enzyme-linked immunosorbent assay (ELISA) involve link-
ing a protein-speciﬁc antibody to an enzyme (e.g., horse-
radish peroxidase), which then processes common con-
jugated substrates to yield an absorbance reading that is
proportionaltotheamountofantibodyboundtotheantigen
being studied. Standard curves using known concentrations
of antigen are made so that the absorbance can be used to
ascertain the unknown concentration of the antigen. The
sandwich variation of ELISA is most commonly used to
study BDNF levels. Recently, a product has been designed
to speciﬁcally detect proBDNF via ELISA (Adipobioscience),
but these do not appear to have been widely used asNeural Plasticity 3
of yet; most studies have utilized standard BDNF ELISA,
which is unable to discriminate between mBDNF and
proBDNF.
Prior to BDNF ELISA, BDNF mRNA levels served as the
most common measure of cellular BDNF content. It was
clear using RT-PCR or in situ hybridization techniques that
BDNF transcripts increase in an activity-dependent manner
[18], but the amount of BDNF protein being produced could
not be quantiﬁed because of very small endogenous con-
centrations [19]. The ﬁrst experiment to use BDNF ELISA
deﬁnitivelyshoweddiscrepanciesbetweenBDNFmRNAand
protein levels; there were numerous temporal and spatial
diﬀerences in the dynamics of the mRNA and protein,
suggestinginvolvementofposttranslationalmechanismsthat
rendered BDNF mRNA an incomplete measure of the pres-
ence of BDNF [19]. There are now commerciallyavailable
kitsforBDNFELISA(Promega’sBDNFEmaxImmunoAssay
System) that have become a staple in studies comparing
BDNF levels across diﬀerent brain regions and experimental
groups [20]. Additionally, a variant named BDNF ELISA
in situ has been shown to be much more accurate in
detecting release of endogenous BDNF in primary neuronal
cultures, making it possible to detect the minute changes in
extracellular BDNF that occur upon electrical stimulation
[13].
With BDNF ELISA, temporal and spatial information
cannot be attained—only the amount of BDNF present or
released in a sample throughout a protracted time span
can be determined [21]. The major advantages in using
ELISA are genetic manipulation is not necessary; blood
serum levels of BDNF are reﬂective of brain BDNF levels
[22] and can be readily measured in human subjects using
BDNF-ELISA [23]; endogenous BDNF release and/or levels
can be detected at a sensitivity of 1–3pg/mL [19, 24]; and
BDNF can be measured without destroying the tissue being
studied—perfused liquids can be measured for their BDNF
content [13, 25]. These last two points are particularly
important in that they oﬀer BDNF ELISA an advantage over
Western immunoblotting. However, Western immunoblots
canbemorespeciﬁcthanELISAindistinguishingBDNFand
proBDNF [26], and in elucidating the cascades involved in
BDNF signaling eﬀects [9].
3. BDNF-eGFP
Several types of mammalian proteins have been tagged
with wildtype green ﬂuorescent protein (GFP) from the
jellyﬁsh Aequorea victoria and, given that the subcellular
localization of the fusion proteins are intact, these tagged
proteins allow the study of their traﬃcking mechanisms
(reviewed in [27]). The ﬁrst BDNF-eGFP fusion protein
was generated by inserting the rat preproBDNF gene into a
CMV promoter-driven vector expressing eGFP using DNA
recombination [28]. The primary localization of BDNF-
eGFP to somatodendritic compartments matched previous
immunocytochemical ﬁndings, showing that BDNF-eGFP
was traﬃcked identically to the endogenous BDNF protein
[28]. Importantly, the synthesis and posttranslational pro-
cessing of BDNF-GFP were also reported to be largely the
same as endogenous BDNF [11, 28] .H o w e v e r ,ar e c e n ts t u d y
showed that the ratio of proBDNF-eGFP/mBDNF-eGFP is
higher than the endogenous proBDNF/mBDNF ratio [29].
BDNF-eGFPoﬀeredtheabilitytoimagedynamicactivity
of BDNF, enabling the discovery that BDNF travels trans-
synaptically in an activity-dependent manner, providing
great support that BDNF is involved in synaptic plasticity
[11]. Anterograde transport and release from axon terminals
[11], autocrine and paracrine dendritic BDNF release [12],
and the need for back-propagating action potentials in
dendritic release [30] are among other important ﬁndings
thatwereonlypossiblewithtime-lapseBDNF-eGFPimaging
in live neurons. However, higher than endogenous levels of
BDNF expression have been necessary thus far to aid in the
visualization of BDNF-eGFP [28, 31].
A unique advantage oﬀered by ﬂuorescent tagging is
the ability to observe BDNF traﬃcking, which involves
packaging, transport, and localization of BDNF. With traf-
ﬁcking abnormalities implicated in Alzheimer’s disease [32],
Huntington’s disease [33], and others (reviewed in [34]), the
ability to image BDNF with temporal and spatial resolution
is critical. Issues with BDNF-eGFP include overexpression
of BDNF, inability to distinguish mBDNF and proBDNF,
transfection is often ineﬃcient and/or harsh, and there is a
requirement for in vitro preparation.
Figure 1 shows an example of a hippocampal neuron in
primary culture after transfection with BDNF-eGFP, with
subsequent immunolabeling with SGA2, a marker of secre-
tory granules. This image shows that BDNF-eGFP is traf-
ﬁcked into SGA2-positive secretory granules, evidence that
it is processed similarly to endogenous BDNF. We are
currently using this approach for time-lapse imaging of
BDNF traﬃcking in neurons obtained from Mecp2-deﬁcient
mice, a model of Rett syndrome (see below).
Several methods for introduction of the BDNF-eGFP
construct are available, including liposome-based reagents
(e.g.,Lipofectamine)andviraltransductions.Viraltransduc-
tionmayoﬀeragentlermethodofinducingtheexpressionof
BDNF-eGFP in cells. The landmark study by Egan et al. [35]
transducedBDNF-eGFPplasmidsintohippocampalcultures
using a Sindbis virus in their discovery that val-BDNF
is traﬃcked diﬀerently than met-BDNF (discussed below,
[35]). Several studies have since used Sindbis virus-mediated
transduction to investigate traﬃcking and release of variants
of BDNF [36]. One mouse model has been developed in
which the human BDNF (hBDNF) gene with a C-terminal
eGFP gene was integrated into the mouse genome [37].
The hBDNF-eGFP gene, particularly its exons I and IV, is
upregulated in response to neuronal activity, recapitulating
the behavior of wildtype mouse BDNF [38]. However,
hBDNF-eGFP in this mouse line is expressed in addition
to the endogenous untagged BDNF, which leads to BDNF
overexpression with unknown consequences [38]. A knock-
in mouse model in which the endogenous BDNF is replaced
by eGFP-tagged BDNF would be a way to circumvent the
issue of BDNF overexpression that is prevalent in BDNF-
eGFP research. Because of the incredible complexity of the4 Neural Plasticity
Figure 1: A pyramidal neuron expressing BDNF-eGFP. Insert
shows BDNF-eGFP puncta in dendrites, which colocalize with the
secretory granule marker SG2 (red).
rodent BDNF gene, a BDNF-eGFP knock-in mouse has been
diﬃcult to generate. However, knock-in mice have been
generated that replace wildtype BDNF with the val66met
BDNF polymorphism [39]. Thus, a knock-in BDNF-eGFP
mouse is plausible and would be an important advancement
in BDNF research, as it could even open the possibility
for live in vivo imaging of BDNF at least in the cerebral
and cerebellar cortices, which are accessible to multiphoton
excitation microscopy through thinned skulls or cranial
windows.
4. BDNF-pHluorin
Because of a vesicular proton ATPase, the lumen of secretory
granules (including neurotransmitter-containing vesicles) is
typically at pH ∼ 5.5, meaning that a protein with pH
sensitivity in this range can be used as an optical indicator
of vesicular release. Genetic mutagenesis of key amino acids
that surround the chromophore in wildtype eGFP-generated
pHluorin, a mutant with its ﬂuorescence intensity highly
variable in the 5.5–7.4 pH range [83], taking advantage of
natural variations in ﬂuorescence that occur in the four
diﬀerent protonation states of the GFP chromophore [84].
Synaptobrevin, a membrane protein involved in vesicular
release, was tagged on its luminal portion with pHluo-
rin [83]. Because pHluorin ﬂuorescence increases upon
exposure to the extracellular environment, it was clear
when and where synaptobrevin-containing vesicles fused
[83], illustrating how tagging proteins with pHluorin can
provide information that standard eGFP tagging cannot.
However, when pHluorin-containing vesicles are quenched,
they hardly ﬂuoresce, meaning that pHluorin cannot be used
in monitoring vesicle traﬃcking. An additional concern is
that, if pHluorin-tagged proteins diﬀuse out of a vesicle
(i.e., cargoes like BDNF), there is a net ﬂuorescence decrease
because the local concentration of pHluorin molecules
decreases sharply when vesicle fusion is sustained [10, 85].
Similar to BDNF-eGFP, experimental concerns for BDNF-
pHluorin include overexpression of BDNF and potentially
harshtransfectionmethods;sofar,viraltransductionhasnot
been used for BDNF-pHluorin.
BDNF-pHluorin was ﬁrst used in the discovery that
synaptotagmin-4 (syt4) regulates exocytosis of BDNF secre-
tory vesicles [85]. This chimeric protein was also used to
characterize BDNF release in response to diﬀerent types
of stimulation; theta burst stimulation (TBS) and other
LTP-inducing stimulations showed the highest amounts of
BDNF release [10]. These two papers comprise the entire
body of published BDNF-pHluorin research. Both studies
show thatBDNF-pHluorin ﬂuorescenceincreasestransiently
followingneuronaldepolarizationbutonlyinaxonalpuncta,
meaningthatBDNFvesiclefusionproceedsthoughaprocess
of several repeated fusions, followed by re-acidiﬁcation
and requenching of BDNF-pHluorin, that is, kiss-and-run
(Figure 2). On the other hand, the intensity of BDNF-
pHluorin puncta in dendrites always showed a net decrease
following depolarizing stimulation, indicating full vesicular
fusion and BDNF discharge (Figure 2). However, ﬂuores-
cence increases in the initial fusion events could be detected
in both axonal and dendritic puncta using total internal
reﬂectance ﬂuorescence (TIRF) microscopy and faster image
acquisition rates [10], enabling detection of many types of
single vesicle fusion events. Thus, these studies illustrate how
BDNF-pHluorin can be very useful in determining vesicular
release kinetics of BDNF. It would be of great interest to
investigate if BDNF vesicular release kinetics is altered in
BDNF-related disorders, but none such studies have been
conducted to date.
Figures 3 and 4 show unpublished work from our lab-
oratory using a BDNF-pHluorin plasmid from the Poo
laboratory [10]; same results were obtained with a BDNF-
pHluorin plasmid from the Chapman laboratory [85].
BDNF-pHluorin in cultured hippocampal neurons is sensi-
tive to pH, as demonstrated by its quenching when switching
from artiﬁcial cerebrospinal ﬂuid (ACSF) containing 50mM
ammonium chloride (NH4Cl) to control ACSF (Figure 3).
To conﬁrm the viability of neurons transfected with BDNF-
pHluorin and their responsiveness to extracellular ﬁeld
stimulation, Ca2+ imaging was performed in neurons labeled
with the ﬂuorescent dye fura-2AM. Upon stimulation with
a 1sec-20Hz train at 20V delivered by Pt wires, Ca2+
transiently increased in several dendrites (Figure 4). Using
the same stimulation intensity but for longer duration, den-
dritic BDNF-pHluorin puncta showed activity-dependent
destaining consistent with full fusion and BDNF discharge
from secretory granules (Figure 5). Current studies in our
laboratory use BDNF-pHluorin to study activity-dependent
BDNF release in neurons from a mouse model of Rett
syndrome.
Sofar,allstudiesofBDNFreleaseagreeupontherequire-
mentforintracellularCa2+ elevations,andthevaryingeﬀects
of diﬀerent stimulation frequencies on BDNF release, with
TBS and other LTP-inducing protocols eliciting the greatest
amounts of BDNF secretion [10, 12, 13, 21]. None of the
methods described in this review can provide measures of
the eﬀects of BDNF-receptor signaling. Standard WesternNeural Plasticity 5
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Figure 2: Schematic illustration of how BDNF-pHluorin ﬂuoresces, both inside the vesicle and upon axonal and dendritic vesicular fusion.
Before stimulation, BDNF-pHluorin protein shows little ﬂuorescence. If intracellular calcium increase occurs upon electrical stimulation,
then BDNF-pHluorin vesicle may fuse, opening up to the pH 7.4 extracellular space, causing a transient spike in ﬂuorescence that can be
detected by TIRF microscopy. Diﬀerent styles of fusion between axon and dendrite are shown, as explained in [10] and in the text. After
sustained vesicular fusion as occurs in dendrites, ﬂuorescence will decrease as a result of BDNF-pHluorin diﬀusion out of vesicles. Kiss-and-
run fusion as occurs in stimulated axons will rather show an increase in ﬂuorescence because minimal pHluorin diﬀuses out of the vesicle.
The sticks represent synaptotagmin-4; see [85] for details. Modiﬁed from Figure 4(e) in [85].
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Figure 3: Left panel shows a BDNF-pH expressing hippocampal neuron in the presence of 50mM NH4Cl. Right panel shows the same
cell 80sec after standard ACSF solution was applied. The graph shows the time course of the fractional change of BDNF-pH intensity
(background-subtracted delta F/F0) from pixels within the color-coded regions of interest (ROIs) shown in the panels above. The change
from NH4Cl-containing ACSF to control buﬀer quenches BDNF-pH within acidic secretory granules. Time-lapse was performed in an
invertedmicroscopewithaHg-lampandacooledCCDcamera.Neuronswereimagedwitha60x1.45NAoil-immersionobjective,exposure
times ranged from 50–100ms, and images were taken at 1 frame per second (fps).6 Neural Plasticity
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Figure 4: To conﬁrm the viability of neurons transfected with
BDNF-pH and their responsiveness to extracellular ﬁeld stimula-
tion, Ca2+ imaging was performed in neurons labeled with fura-
2 AM. Upon electrical stimulation through ﬁeld Pt wires, Ca2+
transiently increased in several dendrites. The graph shows the time
courseofbackground-subtracteddeltaF/F0 of380nm-excitedfura-
2 ﬂuorescence intensity (510nm emission) from the colored ROIs
shown in the image. Images taken at 4fps.
immunoblotting, and newly developed immunoﬂuorescence
assays that do not require tissue homogenization [27]c a n
speciﬁcally detect qualitative and quantitative molecular
responses to BDNF, complementing the methods reviewed
here.
5. Applicationto Neurogenetic Disorders
5.1. Val66Met BDNF Polymorphism. An estimated 30–50%
of people worldwide are homozygous or heterozygous for a
single nucleotide polymorphism (SNP) that has only been
observed in the human BDNF gene [40]. With this SNP,
valineischangedtomethionineinthe66thresidueofthepro
region of proBDNF. This mutation has not been shown to
aﬀect expression or signaling of mature BDNF, but improper
sorting of met-BDNF-GFP from the trans-Golgi network
into secretory vesicles dramatically reduced the amount of
vesicles in dendritic compartments, leaving much of the
met-BDNF-GFP in the perinuclear region rather than in
synaptic regions [35, 41]. Using BDNF ELISA with chronic
KCl depolarization, it was very evident that the activity-
dependent release of met-BDNF was substantially less, but
constitutive release of val-BDNF and met-BDNF was nearly
identical [35]. Coimmunoprecipitation showed that the
protein sortilin binds to the pro region of BDNF and directs
it from the trans-Golgi network into the regulated secretory
pathway; the association with sortilin was stronger in val-
BDNF than it was in met-BDNF, explaining the traﬃcking
defects observed with met-BDNF [14].
Behavioral and fMRI studies of the consequences of the
Val66Met BDNF polymorphism were the ﬁrst to link human
behavior and brain morphology with BDNF action [40].
Subjects heterozygous for met-BDNF scored signiﬁcantly
lower on episodic memory tasks, but not a factual recall task
[35]. These results emphasize the importance of regulated
BDNF release in memory, particularly in the hippocampus,
where BDNF mRNA expression is highest [42], and where it
promotes the survival and diﬀerentiation of newborn neu-
rons [43]. Additional inﬂuences of the BDNF polymorphism
were seen in fMRI studies, which revealed that hippocampal
activation patterns were abnormal during a memory task
[35], and hippocampal and dorsolateral prefrontal cortex
volumes were ∼10% less in met-BDNF carriers [17].
The results from these behavioral and imaging studies
illustrate a range of macroscopic eﬀects that can be predicted
by studies of molecular activity: less overall BDNF is being
released [35] and several lines of evidence suggest that cleav-
age of met-proBDNF into mature BDNF is impaired com-
pared to val-proBDNF, meaning that LTP and dendritic
arborization will be further impaired because of reduced
TrkB activation. In colocalization studies using BDNF-YFP
(yellow ﬂuorescent protein), it was recently shown that
an association between sortilin and proBDNF at the TGN
facilitates cleavage of proBDNF by the protease furin [44].
Because met-proBDNF binds less strongly to sortilin than
val-proBDNF, it is highly plausible that cleavage of met-
proBDNF is less eﬃcient than cleavage of val-proBDNF.
Additionally, proBDNF-GFP was shown to be copackaged
into dense-core granules of the activity-dependent secre-
tory pathway with tissue plasminogen activator (tPA) and
plasminogen—two proteins that interact to make plasmin
[45, 46]. This means that met-proBDNF is no longer colo-
calized to secretory granules with its primary extracellular
protease, so that proBDNF may predominate over mBDNF
in the extracellular space. Recent evidence corroborates this
idea—the extracellular ratio of mBDNF:proBDNF dramati-
cally increased under depolarizing conditions [29]; without
proper activity-dependent release, this ratio maybe reduced,
and less mBDNF-TrkB signaling may help to explain the
deﬁcits in memory and hippocampal volume seen in Met-
BDNF carriers. This latter study illustrates how BDNF-eGFP
can be useful in methods besides ﬂuorescence microscopy:
anti-GFP antibodies were used to pull down BDNF-eGFP
and proBDNF-eGFP in cellular media, and western blot-
ting then quantiﬁed relative amounts of BDNF-eGFP and
proBDNF-eGFP to show that mBDNF is the dominant
species released following high-frequency stimulation [29].
The extracellular mBDNF:proBDNF ratio has yet to be
directly studied in Val66Met. This would be an important
aspect of the disorder to study, given that extracellular
cleavageofproBDNFisessentialforLTP,andproBDNFpref-
erentially binds the p75 receptor, which has pro-apoptotic
cascades [45, 47].
5.2.NeurodevelopmentalDisordersAssociatedwithIntellectual
Disabilities. There is a well-studied link between the impair-
ment of activity-dependent reﬁnement of synapses and theNeural Plasticity 7
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Figure 5: Neuron expressing BDNF-pHluorin and loaded with the Ca2+ indicator fura-2 AM (image is of 488nm-excited BDNF-pHluorin).
This cell was sensitive to pH (as in Figure 4)a n dr e s p o n d e dt oe l e c t r i c a ls t i m u l a t i o nw i t hC a 2+ transients (using 380nm excitation, as in
Figure 5). Consistent with activity-dependent BDNF release, dendritic BDNF-pHluorin puncta show decreases in intensity (∼20% deltaF/F)
as a result of BDNF-pHluorin discharge from vesicles following full fusion.
neurodevelopmental disorder Rett syndrome (RTT), a debil-
itating disorder that aﬀects ∼1:15,000 females worldwide
(reviewed in [34]). Rett syndrome ﬁrst manifests itself 6–18
months after birth, with common symptoms being diﬃculty
breathing and deterioration of acquired motor, language,
and social skills [48]. Origins of the disorder have been
conﬁrmed to be mutations that yield loss of function in
MECP2, a gene on the X chromosome that encodes for the
transcriptional regulator protein MeCP2. MeCP2 binds to
A/T-rich sites near methylated CpG islands and can recruit
transcriptional repressor and/or activator proteins that can
then modify chromatin (reviewed in [49]). Interestingly, one
of the many genes regulated by MeCP2 is the Bdnf gene.
BDNF mRNA levels are lower in autopsy brain samples
from RTT individuals [50]a n dB D N Fp r o t e i nl e v e l sa r e
decreased in Mecp2-deﬁcient mouse models, with more
severe decreases in BDNF are associated to more severe RTT-
like symptoms [51]. The mechanisms underlying MeCP2
controlofBDNFhavelongbeendebated,butrecentevidence
shows that MeCP2 acts to repress transcription of multiple
microRNAs that bind to the 3 UTR region of BDNF mRNA
and subsequently reduce BDNF protein levels, as measured
by ELISA [52]. This ﬁnding may explain how loss of MeCP2
function leads to impaired BDNF expression.
The inﬂuence of BDNF on RTT is widespread. Autopsies
showed that, in hippocampus [53] and neocortex [54]o f
RTT patients, there was a pronounced decrease in dendritic
growth and spine density (but see [55]). This is possibly
explained by the reduced expression and phosphorylation
of microtubule-associated protein 2 [54], processes which
are both modulated by BDNF [56]. Increased expression
of BDNF, measured by Western blots [57], BDNF-GFP
[31], or ELISA [58], caused improvements in synaptic
function, dendrite length, and respiratory function in Rett
syndrome mouse models. RTT patients with the Val66Met
BDNF polymorphism showed more severe symptoms and
an increase in the risk of seizure onset, suggesting that
BDNF traﬃcking and secretion are altered in RTT, not just
BDNF expression levels [59]. This idea gains credence with
ELISA in situ evidence that the total amount of activity-
dependent BDNF release is equal to wildtype levels in the
Mecp2-/y mouse model, even when BDNF expression was
less than half wildtype levels and constitutive secretion was
lessthanwildtypelevels[16].Thus,alargerreadilyreleasable
pool (RRP) of BDNF in RTT was suggested, but BDNF
ELISA cannot conﬁrm this; BDNF-eGFP should be used to
follow up this investigation because it can reveal the relative
quantities of BDNF vesicles that localize to neurites and
therefore can help to uncover an altered RRP of BDNF
vesicles in RTT.
Dendritic spine morphology is regulated by activity-
dependent BDNF release and synthesis [60]. Abnormal
spine morphologies have long been associated with genetic
neurodevelopmental disorders, particularly RTT and Fragile
X syndrome (FXS) [61, 62]. Postmortem studies of RTT
patients showed reduced dendritic spine density in the
hippocampus,withagreaterratioofthin/maturespinesthan
in wildtype hippocampus [63]. To aid in future investiga-
tions, induced pluripotent stem cells (iPSCs) were recently
generated from RTT patient ﬁbroblasts and were diﬀerenti-
ated into neurons that recapitulated many characteristics of
neuronsinRTTpatients,namely,reducedspinedensity[63].
Mature neurons and proliferative neural precursor cells were
generated in the process, opening the exciting possibility
of sustaining cell lines that recapitulate the RTT phenotype
[63]. iPSCs derived from patients aﬄicted with a neuroge-
netic disorder open an exciting new avenue in neuroscience
research, which thus far has been seldom utilized in studying
the involvement of BDNF in neuropathologies.
In Fragile X syndrome, an inherited autism-spectrum
disorder associated with intellectual disability that aﬀects
1:4000 males and half as many females, mutations in
the FMR1 gene cause a functional absence of Fragile X
mental retardation protein (FMRP), a protein that reduces
translation by recruiting 4E-BP proteins to the 5  end
of mRNAs [64, 65]. Importantly, FMRP can also work
to increase translation by transporting mRNA, such as
Rab3a and BDNF mRNA to neurites [65, 66]. Indeed,
levels of Rab3a protein, which is important in activity-
dependent dense core vesicle docking and fusion at the8 Neural Plasticity
pre-synaptic terminal, were substantially reduced in tissues
from Fmr1 knockout mice, causing dysfunctional release
of neuropeptide vesicles [65]. This ﬁnding might provide
an explanation as to why hippocampal neurons from Fmr1
knockout mice show impaired LTP that can be restored
by application of recombinant BDNF, even though levels
of proBDNF and mBDNF were not signiﬁcantly diﬀerent
between wildtype and Fmr1 knockout mice [67], and BDNF
was in fact increased in the hippocampus of Fmr1 knockout
mice in another study, as measured by BDNF ELISA [66].
Considering that the levels of BDNF are not negatively
aﬀected by loss of FMRP function, but dense core vesicle
docking is aﬀected, it is very plausible that BDNF vesicle
docking and fusion is aﬀected in FXS, contributing to the
observed deﬁcits in LTP and learning [68]. Additionally,
one study has linked BDNF traﬃcking with FXS symptoms,
showinganincreasedpropensityforepilepsyinFXS-aﬄicted
men who have the improperly sorted met-BDNF allele [69].
Future studies utilizing BDNF-eGFP or BDNF-pHluorin
in neurons from FXS models could elucidate the ways in
which BDNF traﬃcking and vesicle fusion are aﬀected in
FXS, providing clues as to why LTP and dendritic spine
maturation are impaired in FXS.
There is also evidence that BDNF is upstream of FMRP
activity: BDNF, but not neurotrophin-3 application, and
overexpression of TrkB was shown to slightly reduce the
expression of the Fmr1 gene, implicating BDNF-TrkB sig-
naling in the negative regulation of FMRP levels [70];
BDNF also caused dissociation of the FMRP translational
repressioncomplex,allowingtranslationtooccurspeciﬁcally
in dendritic compartments [64]. The impact of abnormal
communication between BDNF and FMRP that is expected
to occur in FXS has not been extensively studied (see [66]),
and deserves further investigation.
5.3. Huntington’s Disease. In contrast to the neuropatholo-
gies discussed thus far, Huntington’s disease (HD) is a neu-
rodegenerative disorder with symptoms usually appearing
in middle age [71]. Its most characteristic symptoms are
related to loss of motor function as a result of basal ganglia
degeneration, but often before motor symptoms become
manifest there are cognitive deﬁcits in verbal learning and
working memory, tasks associated with hippocampal and
prefrontal areas [72]. HD is a rare inherited disorder that
aﬀects 5–10 in 100,000 Caucasians, with fewer reported cases
in Japanese populations [73]. HD is associated with 36 or
greater CAG repeats in the huntingtin gene, producing an
abnormal huntingtin protein (htt) with an extended tract of
glutaminethatisencodedbytheCAGrepeats.Theseverityof
the disease is proportional to the number of CAG repeats, as
the polyglutamine tail causes self-association of htt mutants
that can lead to htt aggregates [73]. Unlike those seen in
Alzheimer’s disease, these mutant htt aggregates do not
have intrinsic toxicity, but vesicle traﬃcking and endocytic
recycling are severely impaired in mutant htt, leading to
dendritic spine degeneration and eventual cell death ([74,
75], but see [76]).
BDNF-eGFP vesicles colocalized with wildtype and
mutant htt, but only wildtype htt was shown to increase
velocity and eﬃciency of BDNF transport to synapses. This
eﬀect appeared speciﬁc for BDNF vesicles, as mitochondrial
transportwasunaﬀected[33].htt-mediatedaxonaltransport
of BDNF requires Huntington-associated protein 1 (HAP1);
HAP1 associates with the pro domain of BDNF-eGFP,
and this association is reduced with mutant htt and with
met-BDNF [15], likely because of impaired complexation
with sortilin [44]. This ﬁnding suggests impaired activity-
dependent release and axonal transport, but normal con-
stitutive release, in HD as a result of improper proBDNF-
HAP1-htt interactions. The importance of this ﬁnding is
apparent when considering that the striatum, the region
deﬁnedbyneurodegenerationinHD,containsverylowlevels
of BDNF mRNA [77] but still requires BDNF protein for
survival of striatal inhibitory neurons in mouse HD models
[20, 78]. This means that the striatum requires anterograde
corticostriatal transport of BDNF in order to avoid striatal
degeneration [77–79]. Thus, as revealed by BDNF-GFP, the
abnormal anterograde traﬃcking of BDNF by htt and HAP1
is a major component of striatal neuron degeneration in HD.
Transcription of the Bdnf gene is also aﬀected in HD.
When wildtype htt was overexpressed, BDNF ELISA showed
higher levels of BDNF, and the opposite eﬀect was seen
with mutant htt. This is a result of wildtype htt releasing
the transcriptional repressor REST/NRSF from a 23bp DNA
sequence called RE1/NRSE that was discovered in one
particular Bdnf exon. Mutant htt was unable to derepress
transcriptionoftheBdnf gene,explainingthereducedBDNF
levels seen in HD brains (reviewed in [80]). Other studies
corroborate these data, ﬁnding that cortical levels of BDNF
mRNA negatively correlate with the progression of HD in
am o u s em o d e l[ 81], and that overexpression of forebrain
BDNF results in increased levels of striatal BDNF, and
signiﬁcant reduction in HD phenotype mouse model [26].
With so many facets of HD mediated by BDNF, there is
a clear potential for pharmacological applications: upreg-
ulation of BDNF by activity-inducing ampakines restored
synaptic plasticity and memory in hippocampus of an HD
mousemodelbystabilizingactinpolymerizationindendritic
spines, a process severely impaired in HD [82]. BDNF-GFP
traﬃcking studies, and BDNF ELISA studies of protein levels
have proven invaluable thus far in elucidating the role of
BDNF in HD. However, the quantal release of BDNF in HD
has yet to be visualized, an application well suited for BDNF-
pHluorin.
6. Conclusion
BDNFisaneuropeptidewithadiversearrayoffunctionsthat
modulate neuronal function during early brain development
and throughout life. The dynamics of its intracellular trans-
port and activity-dependent regulated release are complex
and require sophisticated approaches that are currently in
development. To start, methods to study BDNF transport
and release must be dynamic in order to properly follow itsNeural Plasticity 9
behavior in live cells. Thanks to the development of BDNF-
GFP and BDNF-pHluorin, we are beginning to understand
the ways in which BDNF contributes to neuronal function in
health and disease. Therapies are currently being developed
that will aid in restoring BDNF abnormalities to normal,
thereby slowing the progression of diseases like Huntington’s
andRettsyndrome.Futurestudiescanusethetoolsdiscussed
in this review to test the eﬃcacy of experimental compounds
on BDNF transport and release, using the restoration of
proper BDNF dynamics as a preclinical endpoint. Hopefully,
these studies will yield novel therapies for the wide range of
neurogenetic disorders associated with BDNF dysfunction.
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